Group |
Non-progressed group | 52(60.5%) | 36(58.1%) | | |
Progressed group | 34(39.5%) | 26(41.9%) | | |
Time of progression, days | 5.5 (1.0–9.0) | 5.0 (3.0–9.8) | | |
Age, years | 50.5(37.0–60.5) | 44.5(35.0–53.0) | | |
Age range, years |
<40 | 27(31.4%) | 21(33.9%) | | |
40–49 | 15(17.4%) | 14(22.6%) | | |
50–59 | 22(25.6%) | 15(24.2%) | | |
60–69 | 13(15.1%) | 9(14.5%) | | |
70–79 | 7(8.1%) | 2(3.2%) | | |
≥80 | 2(2.3%) | 1(1.6%) | | |
Female | 45(52.3%) | 36(58.1%) | | |
Comorbidity | 42(48.8%) | 15(24.2%) | 3.436(1.084–10.896) | 12× (0/1; no=0, yes=1) |
Dyspnea on admission | 11(12.8%) | 6(9.7%) | 4.869(0.760–31.212) | 16× (0/1; no=0, yes=1) |
Temperature on admission, °C | 36.8(36.5–37.2) | 36.8(36.5–37.1) | | |
Respiratory rate on admission | 19.0(18.0–20.0) | 20.0(19.0–20.0) | | |
Lactate dehydrogenase, U/L | 214.0(187.8–275.8) | 201.5(160.3–247.0) | 1.008(1.001–1.014) | 0.07×per unit (U/L) |
Procalcitonin, ng/mL | 0.04(0.03–0.07) | 0.03(0.02–0.05) | | |
Lymphocyte count, 109 /L | 1.2(0.9–1.6) | 1.3(1.0–1.7) | 0.134(0.038–0.471) | −20×per unit (109/L) |
White blood cells, 109 /L | 4.8(3.7–6.1) | 4.7(4.0–6.1) | | |
Neutrophil count, 109/L | 3.1(2.2–4.1) | 3.0(2.0–3.9) | | |
Platelet count, 109/L | 159.3(132.5–204.0) | 164.5(120.3–210.4) | | |
Hemoglobin concentration, g/L | 138.5(127.0–156.6) | 143.3(130.0–152.8) | | |
Arterial oxygen saturation (%) | 97.0(95.3–98.8) | 96.0(95.0–98.0) | | |
Radiological abnormality |
GGOSS | 36(41.9%) | – | | |
Pure ground-glass opacity | 32(37.2%) | – | | |
Consolidation | 12(14.0%) | – | | |
Other | 6(7.0%) | – | | |
No. of affected segments | 7.0(2.3–12.0) | - | | |
Lesion size |
<1 cm | 4(4.7%) | – | | |
1–3 cm | 32(37.2%) | – | | |
3 cm–50% lobe | 45(52.3%) | – | | |
>50% lobe | 5(5.8%) | – | | |
AI-based volume ratio of pneumonia |
−700∼500 | 0.18(0.11–0.27) | – | | |
−600∼500 | 0.11(0.07–0.17) | – | | |
Treatment |
Corticosteroid agents | 55(64.0%) | 19(30.6%) | | |
Anti-infection agents | 85(98.8%) | 52(83.9%) | | |
Interferon agents | 34(39.5%) | 7(11.3%) | | |
Antiviral agents | 74(86%) | 61(98.4%) | | |
Gamma globulin agents | 54(62.8%) | 21(33.9%) | | |